Information  X 
Enter a valid email address

Antisoma plc (SRC)

  Print      Mail a friend       Annual reports

Tuesday 05 September, 2006

Antisoma plc

Second dramatic response seen with Antisoma's A...

London, UK and Louisville, Kentucky, 5 September 2006 - Antisoma
today announces that a second late-stage renal cancer patient in its
phase I trial of AS1411 has experienced major tumour shrinkage. This
follows a similar case reported earlier from the same trial.

The latest responder had four separate tumours at different sites,
with an aggregate total diameter before treatment of almost 20cm. Six
months after starting treatment with AS1411 overall tumour shrinkage
was around 70%, clearly qualifying as a partial response. This
outcome is particularly notable because the patient had relapsed
after three prior therapies: interleukin-2, gemcitabine and
interferon plus Avastin.

Dr Damian Laber, Principal Investigator in the trial commented: "It
is exciting to see a second case of profound tumour shrinkage in this
relatively small study. We are particularly encouraged to see a
response like this in a patient who has already failed several
previous therapies."

Full data from the AS1411 trial will be presented at the European
Society of Medical Oncology (ESMO) meeting on October 1st by
Professor Donald Miller, Director of the Brown Cancer Center in
Louisville, Kentucky, where the trial was conducted. Following its
extension last year, the trial includes twelve patients with renal
cancer and five with lung cancer.

Glyn Edwards, Antisoma's CEO, said: "We are delighted to see further
clinical evidence for AS1411 activity against renal cancer. We are
also seeing activity across a wide range of other solid and blood
cancers in preclinical studies. These findings, together with the
very benign safety profile seen so far, make us very excited about
the potential of AS1411."

Glyn Edwards, CEO
Daniel Elger, Director of
Communications                                 +44 (0)20 8799 8200
Antisoma plc

Mark Court/Lisa Baderoon/Rebecca Skye Dietrich                   +44
(0)20 7466 5000
Buchanan Communications

Except for the historical information presented, certain matters
discussed in this statement are forward looking statements that are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from results, performance or
achievements expressed or implied by such statements. These risks and
uncertainties may be associated with product discovery and
development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.

Notes for Editors:
The response of tumours to treatment is commonly measured using
RECIST (Response Evaluation Criteria in Solid Tumours) to evaluate
tumours imaged on CT or other scans. Possible outcomes include
complete response (disappearance of all tumours), partial response
(more than 30% but less than 100% reduction in the sum of the longest
diameters of 'target' tumour lesions), stable disease (between a 30%
reduction and a 20% increase in the sum of lesion measurements) and
progressive disease (greater than 20% increase in the sum of lesion
sizes or appearance of new lesions). The patient described in this
release therefore had a clear partial response.

Background on Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that
develops novel products for the treatment of cancer. Antisoma fills
its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions. Its core activity is the preclinical and
clinical development of these drug candidates. Please visit for further information about Antisoma.